354 related articles for article (PubMed ID: 1806471)
1. A giant prolactinoma and the effect of chronic bromocriptine therapy on basal and TRH-stimulated serum prolactin levels.
Barrera CM; Ruiz AE; Banks WA
Horm Res; 1991; 35(3-4):167-9. PubMed ID: 1806471
[TBL] [Abstract][Full Text] [Related]
2. Resistance to bromocriptine in prolactinomas.
Pellegrini I; Rasolonjanahary R; Gunz G; Bertrand P; Delivet S; Jedynak CP; Kordon C; Peillon F; Jaquet P; Enjalbert A
J Clin Endocrinol Metab; 1989 Sep; 69(3):500-9. PubMed ID: 2760167
[TBL] [Abstract][Full Text] [Related]
3. [Primary hyperprolactinemic amenorrhea. Report of 4 patients].
Rudolf K; Smid I; Kunkel S; Bazsa-Kassai Z
Zentralbl Gynakol; 1985; 107(14):894-8. PubMed ID: 3929499
[TBL] [Abstract][Full Text] [Related]
4. Partial hypopituitarism and hyperprolactinemia: successful induction of ovulation with bromocriptine and human menopausal gonadotropins.
Dawood MY; Jarrett JC; Choe JK
Fertil Steril; 1982 Oct; 38(4):415-8. PubMed ID: 6811337
[TBL] [Abstract][Full Text] [Related]
5. Perifusion studies of bromocriptine-treated and untreated macroprolactinomas: effects of dopamine, bromocriptine and TRH.
Bevan JS; Burke CW
Clin Endocrinol (Oxf); 1989 Jun; 30(6):667-80. PubMed ID: 2512041
[TBL] [Abstract][Full Text] [Related]
6. Giant invasive prolactinoma: a case report and review of nine further cases.
Davis JR; Sheppard MC; Heath DA
Q J Med; 1990 Mar; 74(275):227-38. PubMed ID: 2385731
[TBL] [Abstract][Full Text] [Related]
7. Growth of prolactinoma despite lowering of serum prolactin by bromocriptine.
Kupersmith MJ; Kleinberg D; Warren FA; Budzilovitch G; Cooper P
Neurosurgery; 1989 Mar; 24(3):417-23. PubMed ID: 2927618
[TBL] [Abstract][Full Text] [Related]
8. Prolactin secretion after surgery or bromocriptine treatment of prolactinoma.
De Leo V; Petraglia F; Sardelli S; Danero S; Genazzani AR; D'Antona N
Obstet Gynecol; 1987 Jan; 69(1):99-103. PubMed ID: 3099236
[TBL] [Abstract][Full Text] [Related]
9. Hormonal regulation of prolactin release by human prolactinoma cells cultured in serum-free conditions.
Jaquet P; Gunz G; Grisoli F
Horm Res; 1985; 22(3):153-63. PubMed ID: 3932176
[TBL] [Abstract][Full Text] [Related]
10. [Treatment of prolactin-secreting pituitary tumors with bromocriptine].
Katzir D; Rosenberg T; Ramot Y; Gaver-Shavit A; Gilboa Y
Harefuah; 1990 Feb; 118(3):141-5. PubMed ID: 2341064
[TBL] [Abstract][Full Text] [Related]
11. [Macroprolactinoma resistant to bromocriptine].
López-Espinosa E; Ayala AR; Grimaldo J; Kunhardt J; Villanueva C
Arch Invest Med (Mex); 1989; 20(1):1-8. PubMed ID: 2669670
[TBL] [Abstract][Full Text] [Related]
12. [Prolactin-secreting macroadenoma in an adolescent girl: response to the medical treatment and follow-up method].
de Kerdanet M; Lebrethon MC; Lecornu M
Pediatrie; 1993; 48(3):233-6. PubMed ID: 8393981
[TBL] [Abstract][Full Text] [Related]
13. Different responses of growth hormone secretion to guanfacine, bromocriptine, and thyrotropin-releasing hormone in acromegalic patients with pure growth hormone (GH)-containing and mixed GH/prolactin-containing pituitary adenomas.
Lamberts SW; Klijn JG; van Vroonhoven CC; Stefanko SZ
J Clin Endocrinol Metab; 1985 Jun; 60(6):1148-53. PubMed ID: 3923021
[TBL] [Abstract][Full Text] [Related]
14. Reduction of follicle-stimulating hormone (FSH) secretion in FSH-producing pituitary adenoma by bromocriptine.
Berezin M; Olchovsky D; Pines A; Tadmor R; Lunenfeld B
J Clin Endocrinol Metab; 1984 Dec; 59(6):1220-3. PubMed ID: 6436289
[TBL] [Abstract][Full Text] [Related]
15. Bromocriptine for prolactinoma-related dissociative disorder and depression.
Cohen AJ
J Clin Psychopharmacol; 1995 Apr; 15(2):144-5. PubMed ID: 7782492
[No Abstract] [Full Text] [Related]
16. Usefulness of thyrotropin-releasing hormone test, SMS 201-995, and bromocriptine in the diagnosis and treatment of gonadotropin-secreting pituitary adenomas.
Blanco C; Lucas T; Alcañiz J; Davila N; Serrano P; Barcelò B; Estrada J
J Endocrinol Invest; 1994 Feb; 17(2):99-104. PubMed ID: 8006339
[TBL] [Abstract][Full Text] [Related]
17. Bromocriptine suppression of TRH-stimulated prolactin and thyrotrophin release and accompanying inhibition of bromocriptine induced growth hormone release by TRH in normal man.
Brown PM; Bacchus R; Sachs L; Sönksen PH; Wheeler M
Clin Endocrinol (Oxf); 1979 May; 10(5):481-8. PubMed ID: 113143
[TBL] [Abstract][Full Text] [Related]
18. Effect of the new dopaminergic agonist CV 205-502 on plasma prolactin levels and tumour size in bromocriptine-resistant prolactinomas.
Duranteau L; Chanson P; Lavoinne A; Horlait S; Lubetzki J; Kuhn JM
Clin Endocrinol (Oxf); 1991 Jan; 34(1):25-9. PubMed ID: 1672268
[TBL] [Abstract][Full Text] [Related]
19. Resolution of possible paradoxical responses of gonadotropins to thyrotropin-releasing hormone with bromocriptine therapy in a patient with follicle-stimulating hormone-secreting pituitary adenoma.
Mercado-Asis LB; Yasuda K; Ishizawa M; Ishizuka T; Murayama M; Shimokawa K; Miura K
Endocrinol Jpn; 1992 Aug; 39(4):401-6. PubMed ID: 1446655
[TBL] [Abstract][Full Text] [Related]
20. Bromocriptine treatment of prolactin-secreting pituitary adenomas may restore pituitary function.
Warfield A; Finkel DM; Schatz NJ; Savino PJ; Snyder PJ
Ann Intern Med; 1984 Dec; 101(6):783-5. PubMed ID: 6497193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
